\n| Subject<\/td>\n | \nThe 2024 Annual Shareholders' Meeting passes\r\nrelease the prohibition on directors from participation\r\nin competition businesses.<\/pre>\n<\/td>\n<\/tr>\n\n| Date of events<\/td>\n | 2024\/06\/21<\/td>\n | To which item it meets<\/td>\n | paragraph 21<\/td>\n<\/tr>\n | \n| Statement<\/td>\n | \n1.Date of the shareholders meeting resolution:2024\/06\/21\r\n2.Name and title of the director with permission to \r\n engage in competitive conduct:\r\n Director:Fu Hui-Tung\r\n Director:\r\n Excelsior Group Holdings Co., Ltd. Representative:\r\n Chen Tun-Ling\r\n Director:Chang Ming-Cheng\r\n Director:Fu Jo-Hsuan\r\n3.Items of competitive conduct in which the director \r\n is permitted to engage:\r\n Concurrently serve as a director with the same or \r\n similar business scope as the Company.\r\n4.Period of permission to engage in the competitive \r\n conduct: A director's term of office\r\n5.Circumstances of the resolution (please describe \r\n the results of voting in accordance with Article \r\n 209 of the Company Act): The resolution was adopted \r\n by a majority of the shareholders presentedat the \r\n general meeting who represented two-thirds or more \r\n of the total number of shares represented by the \r\n attending shareholders.\r\n6.If the permitted competitive conduct belongs to the\r\n operator of a mainland China area enterprise, the name\r\n and title of the directors (if it is not the operator\r\n of a Mainland-area enterprise, please enter \u201cN\/A\u201d \r\n below):Director: Chang Ming-Cheng\r\n7.Company name of the mainland China area enterprise and\r\n the director's position in the enterprise:Director of \r\n SinoExcelsior Investment Incorporation.\r\n8.Address of the mainland China area enterprise:\r\n SinoExcelsior Investment Incorporation address:\r\n Room 301-2, Building 1, No. 1089 Kangning Road, \r\n Shanghai, China\r\n9.Operations of the mainland China area enterprise: \r\n SinoExcelsior Investment Incorporation:Corporate \r\n management consulting; Sales of Class I medical \r\n devices; Import and export of goods; Import and export\r\n of technology;Internet sales (excluding sales of \r\n products requiring licenses);Sales agency; Health \r\n consulting services (excluding diagnostic services);\r\n Information consulting services (excluding licensed \r\n information consulting services); Technical services,\r\n Technical development, Technical consulting, Technical\r\n exchange, Technology transfer, Technology promotion; \r\n Marketing planning; Wholesale of cosmetics.\r\n10.Impact on the company's finance and business:None.\r\n11.If the directors have invested in the mainland China \r\n area enterprise, the monetary amount of the investment\r\n and their shareholding ratio:None.\r\n12.Any other matters that need to be specified:None.\r\n<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":" SEQ_NO2 2 Date of announcement 2024\/06\/21 Time of announcement 16:58:46 Subject The 2024 Annual Shareholders’ Meeting passes release the prohibition on directors from participation in competition businesses. Date of events 2024\/06\/21 To which item it meets paragraph 21 Statement 1.Date of the shareholders meeting resolution:2024\/06\/21 2.Name and title of the director with permission to …<\/p>\n The 2024 Annual Shareholders’ Meeting passes release the prohibition on directors from participation in competition businesses.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-9344","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=9344"}],"version-history":[{"count":12,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9344\/revisions"}],"predecessor-version":[{"id":9356,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9344\/revisions\/9356"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=9344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=9344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=9344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | |